(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 November 2011 (24.11.2011)

PCT

(10) International Publication Number
WO 2011/144673 A2

(51) International Patent Classification:
A61K 38/28 (2006.01) *A61K 9/00* (2006.01)
A61K 9/08 (2006.01) *A61K 38/00* (2006.01)
A61P 5/50 (2006.01) *A61K 31/00* (2006.01)
A61P 3/10 (2006.01)

(21) International Application Number:
PCT/EP2011/058079

(22) International Filing Date:
18 May 2011 (18.05.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10305532.3 19 May 2010 (19.05.2010) EP
10305780.8 13 July 2010 (13.07.2010) EP
11305140.3 10 February 2011 (10.02.2011) EP

(71) Applicant *(for all designated States except US)*: **SANOFI** [FR/FR]; 174 avenue de France, F-75013 Paris (FR).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BECKER, Reinhard** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **FRICK, Annke** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **BODERKE, Peter** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **FUERST, Christiane** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **MUELLER, Werner** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **TERTSCH, Katrin** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **WERNER, Ulrich** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **LOOS, Petra** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **SCHOETTLE, Isabell** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).


(74) Agent: **LÖWRICK, Oliver**; K 801, Sanofi-Aventis Deutschland GmbH, Patents Germany, Industriepark Höchst, Geb. K 801, 65926 Frankfurt (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,

[Continued on next page]

(54) Title: LONG - ACTING FORMULATIONS OF INSULINS

Fig. 3 (1/2)



(57) Abstract: The application relates to an aqueous pharmaceutical formulation comprising 200 – 1000 U/mL [equimolar to 200 –1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine, and its use.

WO 2011/144673 A2

SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*